Results 11 to 20 of about 6,115 (159)

Immune-Mediated Thrombocytopenia in an Ulcerative Colitis Patient After Initiating Filgotinib Treatment: A Case Report. [PDF]

Clin Case Rep
Timeline of events ABSTRACT Moderate‐to‐severe ulcerative colitis can be effectively treated with JAK‐1 inhibition, but platelet counts should be closely monitored, especially in active disease. We confirmed immune‐mediated thrombocytopenia (ITP) in one of our patients after the initiation of filgotinib. Whether this was drug‐induced is uncertain.
van der Hoff MJ, El-Morabit F, Löwenberg M.   +2 more
europepmc   +2 more sources

Induction of Colonic Regulatory T Cells by Mesalamine by Activating the Aryl Hydrocarbon ReceptorSummary

Cellular and Molecular Gastroenterology and Hepatology, 2017
Background & Aims: Mesalamine is a first-line drug for treatment of inflammatory bowel diseases (IBD). However, its mechanisms are not fully understood. CD4+ Foxp3+ regulatory T cells (Tregs) play a potential role in suppressing IBD.
Kyoko Oh-oka, Yuko Kojima, Koichiro Uchida, Kimiko Yoda, Kayoko Ishimaru, Shotaro Nakajima, Jun Hemmi, Hiroshi Kano, Yoshiaki Fujii-Kuriyama, Ryohei Katoh, Hiroyuki Ito, Atsuhito Nakao   +11 more
doaj   +1 more source

Efficacy and safety of two pH-dependent-release mesalamine doses in moderately active ulcerative colitis: a multicenter, randomized, double-blind, parallel-group study [PDF]

Intestinal Research, 2016
Background/AimsThe therapeutic effect of mesalamine is considered to be dose-dependent; however, no consensus has been reached regarding the optimal doses for individual patients.
Yasuo Suzuki, Mitsuo Iida, Hiroaki Ito, Isamu Saida, Toshifumi Hibi   +4 more
doaj   +1 more source

Recent advances in mesalamine colonic delivery systems

Future Journal of Pharmaceutical Sciences, 2020
Background Increased attention has been focused on the continuous development and improvement of mesalamine colonic specific delivery systems, for the effective treatment of inflammatory bowel diseases; thus enhancing therapeutic efficacy and reducing ...
Mohammad F. Bayan, Rana F. Bayan
doaj   +1 more source

A Case of Stevens–Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis

Medicina, 2022
A 41-year-old man was treated with prednisolone (PSL) and multimatrix (MMX) mesalamine for remission induction therapy of ulcerative colitis. PSL was tapered due to successful remission induction treatment.
Mimari Kanazawa, Keiichi Tominaga, Akira Kanamori, Takanao Tanaka, Satoshi Masuyama, Shoko Watanabe, Keiichiro Abe, Akira Yamamiya, Kenichi Goda, Atsushi Irisawa   +9 more
doaj   +1 more source

Successful management of HIV infection in a patient with ulcerative colitis; a case report [PDF]

Journal of Preventive Epidemiology, 2021
Human immunodeficiency virus (HIV) is an infectious disease that is rarely seen in ulcerative colitis patients. Both diseases commonly involve the colon.
Zain Majid, Shoaib Ahmed Khan, Hina Ismail, Nishat Akbar, Rajesh Mandhwani, Nasir Luck   +5 more
doaj   +1 more source

Development of Novel pH-Sensitive Eudragit Coated Beads Containing Curcumin-Mesalamine Combination for Colon-Specific Drug Delivery

Gels, 2023
This research aims to develop a drug delivery system that effectively treats colitis while administering curcumin/mesalamine by coating alginate/chitosan beads with Eudragit® S-100 to target the colon. Beads were tested to determine their physicochemical
Eman J. Heikal, Rashad M. Kaoud, Shadeed Gad, Hatem I. Mokhtar, Abdullah Alattar, Reem Alshaman, Sawsan A. Zaitone, Yasser M. Moustafa, Taha M. Hammady   +8 more
doaj   +1 more source

Suppository treatment in ulcerative proctitis

European Journal of Inflammation, 2021
Ulcerative proctitis (UP) is a common form of ulcerative colitis (UC), the number of patients with UP is increasing. Suppository treatment containing mesalamine is usually the first-line choice for mild to moderate UP, here, we review the publications on
Yingjie Si, LanJun Shao, Shanqing Gao, Hongzhu Wen   +3 more
doaj   +1 more source

Mesalamine-Induced Eosinophilic Pneumonia. [PDF]

Cureus
Sharma M, Sotelo JE, Schultz S.
europepmc   +2 more sources

Myocarditis Secondary to Mesalamine-Induced Cardiotoxicity in a Patient with Ulcerative Colitis

Case Reports in Medicine, 2018
Development of cardiac manifestations in patients diagnosed with inflammatory bowel disease undergoing treatment with mesalamine is a rare. When this occurs, it can be difficult to tease out the primary etiology, as both IBD and mesalamine can cause ...
Kelechukwu U. Okoro, Matthew D. Roby, Adegbenga A. Bankole   +2 more
doaj   +1 more source